Investing.com - Ascendis Pharma (NASDAQ:ASND) AS reported on Wednesday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Ascendis Pharma AS announced earnings per share of €-1.46 on revenue of €6.16B. Analysts polled by Investing.com anticipated EPS of €-2.16 on revenue of €5.58M.
Ascendis Pharma AS shares are down 29.28% from the beginning of the year, still down 46.76% from its 52 week high of €178.71 set on September 3, 2021. They are under-performing the Nasdaq which is down 17.83% from the start of the year.
Ascendis Pharma AS shares lost 0.67% in after-hours trade following the report.
Ascendis Pharma AS follows other major Healthcare sector earnings this month
Ascendis Pharma AS's report follows an earnings beat by UnitedHealth on July 15, who reported EPS of €5.57 on revenue of €80.33B, compared to forecasts EPS of €5.21 on revenue of €79.68B.
J&J had beat expectations on July 19 with second quarter EPS of €2.59 on revenue of €24.02B, compared to forecast for EPS of €2.54 on revenue of €23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar